Regulation of DMD pathology by an ankyrin-encoded miRNA

Skeletal Muscle

Volumn 1, Issue 1, 2011, Pages

  Alexander, Matthew S ^a   Casar, Juan C ^a   Motohashi, Norio ^a   Myers, Jennifer A ^a   Eisenberg, Iris ^a   Gonzalez, Robert T ^a   Estrella, Elicia A ^a   Kang, Peter B ^a   Kawahara, Genri ^a   Kunkel, Louis M ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUS; MUS MUSCULUS;

EID: 84863875620     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-1-27     Document Type: Article

References (59)

1. Emery AE. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul Disord 1991, 1:19-29. 10.1016/0960-8966(91)90039-U, 1822774.
2. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928. 10.1016/0092-8674(87)90579-4, 3319190.
3. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loire JD, Harris JB, Waterston R, Brooke M, Specht L, Kupsky W, Chamberlain J, Caskey CT, Shapiro F, Kunkel LM. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988, 318:1363-1368. 10.1056/NEJM198805263182104, 3285207.
4. Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve 2000, 23:1456-1471. 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T, 11003781.
5. Tidball JG, Spencer MJ, St Pierre BA. PDGF-receptor concentration is elevated in regenerative muscle fibers in dystrophin-deficient muscle. Exp Cell Res 1992, 203:141-149. 10.1016/0014-4827(92)90049-E, 1426037.
6. Zhao Y, Haginoya K, Sun G, Dai H, Onuma A, Iinuma K. Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study. J Pathol 2003, 201:149-159. 10.1002/path.1414, 12950028.
7. Yablonka-Reuveni Z, Rivera AJ. Influence of PDGF-BB on proliferation and transition through the MyoD-myogenin-MEF2A expression program during myogenesis in mouse C2 myoblasts. Growth Factors 1997, 15:1-27. 10.3109/08977199709002109, 9401815.
8. Lawlor MA, Rotwein P. Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol Cell Biol 2000, 20:8983-8995. 10.1128/MCB.20.23.8983-8995.2000, 86552, 11073997.
9. Dogra C, Changotra H, Wergedal JE, Kumar A. Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-κB signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J Cell Physiol 2006, 208:575-585. 10.1002/jcp.20696, 16741926.
10. Haslett JN, Sanoudou D, Kho AT, Han M, Bennett RR, Kohane IS, Beggs AH, Kunkel LM. Gene expression profiling of Duchenne muscular dystrophy skeletal muscle. Neurogenetics 2003, 4:163-171. 10.1007/s10048-003-0148-x, 12698323.
11. Feron M, Guevel L, Rouger K, Dubreil L, Arnaud MC, Ledevin M, Megeney LA, Cherel Y, Sakanyan V. PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle. Am J Pathol 2009, 174:1459-1470. 10.2353/ajpath.2009.080460, 2671376, 19264909.
12. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, Lidov HG, Kang PB, North KN, Mitrani-Rosenbaum S, Flanigan KM, Neely LA, Whitney D, Beggs AH, Kohane IS, Kunkel LM. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci USA 2007, 104:17016-17021. 10.1073/pnas.0708115104, 2040449, 17942673.
13. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233. 10.1016/j.cell.2009.01.002, 19167326.
14. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, Kelm RJ, Olson EN. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009, 17:662-673. 10.1016/j.devcel.2009.10.013, 2796371, 19922871.
15. Bennett V, Chen L. Ankyrins and cellular targeting of diverse membrane proteins to physiological sites. Curr Opin Cell Biol 2001, 13:61-67. 10.1016/S0955-0674(00)00175-7, 11163135.
16. Zhou D, Birkenmeier CS, Williams MW, Sharp JJ, Barker JE, Bloch RJ. Small, membrane-bound, alternatively spliced forms of ankyrin 1 associated with the sarcoplasmic reticulum of mammalian skeletal muscle. J Cell Biol 1997, 136:621-631. 10.1083/jcb.136.3.621, 2134284, 9024692.
17. Gallagher PG, Forget BG. An alternate promoter directs expression of a truncated, muscle-specific isoform of the human ankyrin 1 gene. J Biol Chem 1998, 273:1339-1348. 10.1074/jbc.273.3.1339, 9430667.
18. Armani A, Galli S, Giacomello E, Bagnato P, Barone V, Rossi D, Sorrentino V. Molecular interactions with obscurin are involved in the localization of muscle-specific small ankyrin1 isoforms to subcompartments of the sarcoplasmic reticulum. Exp Cell Res 2006, 312:3546-3558. 10.1016/j.yexcr.2006.07.027, 16962094.
19. Giacomello E, Sorrentino V. Localization of ank1.5 in the sarcoplasmic reticulum precedes that of SERCA and RyR: relationship with the organization of obscurin in developing sarcomeres. Histochem Cell Biol 2009, 131:371-382. 10.1007/s00418-008-0534-4, 19002483.
20. Small EM, O'Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD, Richardson JA, Olson EN. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sciences USA 2010, 107:4218-4223.
21. Chargé SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004, 84:209-238. 10.1152/physrev.00019.2003, 14715915.
22. Couteaux R, Mira JC, d'Albis A. Regeneration of muscles after cardiotoxin injury. I. Cytological aspects. Biol Cell 1988, 62:171-182. 10.1016/0248-4900(88)90034-2, 3390626.
23. Maltin CA, Harris JB, Cullen MJ. Regeneration of mammalian skeletal muscle following the injection of the snake-venom toxin, taipoxin. Cell Tissue Res 1983, 232:565-577. 10.1007/BF00216429, 6883457.
24. Haslett JN, Kang PB, Han M, Kho AT, Sanoudou D, Volinski JM, Beggs AH, Kohane IS, Kunkel LM. The influence of muscle type and dystrophin deficiency on murine expression profiles. Mamm Genome 2005, 16:739-748. 10.1007/s00335-005-0053-8, 16261416.
25. Sandri M, El Meslemani AH, Sandri C, Schjerling P, Vissing K, Andersen JL, Rossini K, Carraro U, Angelini C. Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy: a potential target for pharmacological treatment?. J Neuropathol Exp Neurol 2001, 60:302-312.
26. Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane IS, Beggs AH, Kunkel LM. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci USA 2002, 99:15000-15005. 10.1073/pnas.192571199, 137534, 12415109.
27. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, Komuro I. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J 2004, 23:212-220. 10.1038/sj.emboj.7600045, 1271675, 14713953.
28. Lees SJ, Childs TE, Booth FW. Age-dependent FOXO regulation of p27Kip1 expression via a conserved binding motif in rat muscle precursor cells. Am J Physiol Cell Physiol 2008, 295:C1238-C1246. 10.1152/ajpcell.00349.2008, 2584982, 18787071.
29. Huh MS, Parker MH, Scimà A, Parks R, Rudnicki MA. Rb is required for progression through myogenic differentiation but not maintenance of terminal differentiation. J Cell Biol 2004, 166:865-876. 10.1083/jcb.200403004, 2172111, 15364961.
30. Seoane J, Le HV, Shen L, Anderson SA, Massagué J. Integration of Smad and Forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004, 117:211-223.
31. Machida S, Booth FW. Increased nuclear proteins in muscle satellite cells in aged animals as compared to young growing animals. Exp Gerontol 2004, 39:1521-1525. 10.1016/j.exger.2004.08.009, 15501022.
32. Roeb W, Boyer A, Cavenee WK, Arden KC. PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci USA 2007, 104:18085-18090. 10.1073/pnas.0708910104, 2084300, 17986608.
33. Zhang P, Wong C, Liu D, Finegold M, Harper JW, Elledge SJ. p21CIP1 and p57KIP2 control muscle differentiation at the myogenin step. Genes Dev 1999, 13:213-224. 10.1101/gad.13.2.213, 316389, 9925645.
34. Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 1996, 5:1149-1153. 10.1093/hmg/5.8.1149, 8842734.
35. Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A, Ferracin M, Nicoloso MS, Barbarotto E, Popa M, Stanciulea O, Fernandez MH, Tubure D, Bueso-Ramos CE, Negrini M, Calin GA. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One 2009, 4:e7405. 10.1371/journal.pone.0007405, 2756627, 19823581.
36. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N, Rechavi G, Givol D. MIR-451 and imatinib mesylate inhibit tumor growth of glioblastoma stem cells. Biochem Biophys Res Commun 2008, 376:86-90. 10.1016/j.bbrc.2008.08.107, 18765229.
37. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 2009, 4:e8003. 10.1371/journal.pone.0008003, 2777376, 19946373.
38. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007, 28:1379-1386. 10.1093/carcin/bgm052, 17341655.
39. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009, 102:19-65. 2933405, 19595306.
40. Kuwahara K, Barrientos T, Pipes GC, Li S, Olson EN. Muscle-specific signaling mechanism that links actin dynamics to serum response factor. Mol Cell Biol 2005, 25:3173-3181. 10.1128/MCB.25.8.3173-3181.2005, 1069631, 15798203.
41. Kuwahara K, Teg Pipes GC, McAnally J, Richardson JA, Hill JA, Bassel-Duby R, Olson EN. Modulation of adverse cardiac remodeling by STARS, a mediator of MEF2 signaling and SRF activity. J Clin Invest 2007, 117:1324-1334. 10.1172/JCI31240, 1838928, 17415416.
42. Selvaraj A, Prywes R. Megakaryoblastic leukemia-1/2, a transcriptional co-activator of serum response factor, is required for skeletal myogenic differentiation. J Biol Chem 2003, 278:41977-41987. 10.1074/jbc.M305679200, 14565952.
43. Lamon S, Wallace MA, Léger B, Russell AP. Regulation of STARS and its downstream targets suggest a novel pathway involved in human skeletal muscle hypertrophy and atrophy. J Physiol 2009, 587:1795-1803. 10.1113/jphysiol.2009.168674, 2683965, 19255118.
44. Dey BK, Gagan J, Dutta A. miR-206 and -486 induce myoblast differentiation by downregulating Pax7. Mol Cell Biol 2011, 31:203-214. 10.1128/MCB.01009-10, 3019853, 21041476.
45. Seale P, Ishibashi J, Holterman C, Rudnicki MA. Muscle satellite cell-specific genes identified by genetic profiling of MyoD-deficient myogenic cell. Dev Biol 2004, 275:287-300. 10.1016/j.ydbio.2004.07.034, 15501219.
46. Buckingham M, Vincent SD. Distinct and dynamic myogenic populations in the vertebrate embryo. Curr Opin Genet Dev 2009, 19:444-453. 10.1016/j.gde.2009.08.001, 19762225.
47. Seno MM, Hu P, Gwadry FG, Pinto D, Marshall CR, Casallo G, Scherer SW. Gene and miRNA expression profiles in autism spectrum disorders. Brain Res 2011, 1380:85-97.
48. Zwaigenbaum L, Tarnopolsky M. Two children with muscular dystrophies ascertained due to referral for diagnosis of autism. J Autism Dev Disord 2003, 33:193-199. 10.1023/A:1022947728569, 12757359.
49. Ekström AB, Hakenäs-Plate L, Samuelsson L, Tulinius M, Wentz E. Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals with congenital and childhood forms. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:918-926. 10.1002/ajmg.b.30698, 18228241.
50. Hu Z, Wang H, Lee IH, Modi S, Wang X, Du J, Mitch WE. PTEN inhibition improves muscle regeneration in mice fed a high-fat diet. Diabetes 2010, 59:1312-1320. 10.2337/db09-1155, 2874691, 20200318.
51. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 2010, 18:1995-2005. 10.1038/mt.2010.186, 20823833.
52. Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T. The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy. Mol Ther 2011, 19:9-15. 10.1038/mt.2010.219, 20978473.
53. Bennett RR, Schneider HE, Estrella E, Burgess S, Cheng AS, Barrett C, Lip V, Lai PS, Shen Y, Wu BL, Darras BT, Beggs AH, Kunkel LM. Automated DNA mutation detection using universal conditions direct sequencing: application to ten muscular dystrophy genes. BMC Genet 2009, 10:66. 2781300, 19835634.
54. Péault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, Partridge T, Gussoni E, Kunkel LM, Huard J. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 2007, 15:867-877. 10.1038/mt.sj.6300145, 17387336.
55. Park IH, Lerou PH, Zhao R, Huo H, Daley GQ. Generation of human-induced pluripotent stem cells. Nat Protoc 2008, 3:1180-1186. 10.1038/nprot.2008.92, 18600223.
56. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006, 1:241-245. 10.1038/nprot.2006.37, 17406239.
57. Kho AT, Kang PB, Kohane IS, Kunkel LM. Transcriptome-scale similarities between mouse and human skeletal muscles with normal and myopathic phenotypes. BMC Musculoskelet Disord 2006, 7:23. 10.1186/1471-2474-7-23, 1525166, 16522209.
58. Brüning JC, Michael MD, Winnay JN, Hayashi T, Hörsch D, Accili D, Goodyear LJ, Kahn CR. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998, 2:559-569. 10.1016/S1097-2765(00)80155-0, 9844629.
59. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.